Delivery Order SPE2DB20D2104-SPE2DB25FNATT
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 18, 2025, with a ceiling value of $10,325.86. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This delivery order represents a single transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for 90 tablets of Gemtesa 75 mg, with a ceiling value of $5,400.07 under a firm fixed-price delivery order contract. The award was competitively procured with no set-aside designation and is scheduled for completion by September 16, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Gemtesa 75 mg tablets (30-count packages) with a contract ceiling value of $4,316.81. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The order is to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a contract ceiling value of $27,331.63. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order has an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $12,673.62 delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price contract, which involves no set-aside designation, represents a competitively awarded delivery order under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $6,194.63. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $2,679.48. This delivery order, with an ultimate completion date of July 22, 2025, represents a small-value pharmaceutical procurement with no set-aside designation, indicating the award was made through competitive procedures. The contract will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $22,655.56 delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of June 11, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $25,148.50 for 90-tablet supplies of Gemtesa 75 mg tablets under a firm fixed-price contract. The award, made on September 15, 2025, with an ultimate completion date of September 16, 2025, represents a competitively awarded, non-set-aside procurement. Performance of this delivery order is based in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNATTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $1,389.38. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of September 18, 2025. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor for the Defense Logistics Agency, AmerisourceBergen serves critical medical supply chain needs for military and veteran healthcare systems, delivering a comprehensive range of pharmaceuticals and medical supplies across multiple therapeutic domains. The company's federal contracting portfolio demonstrates consistent competitively-awarded orders across diverse medical products and dosages, positioning it as a significant provider within the federal medical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 9/17/25 |